PALO ALTO, Calif., Feb. 21, 2012 /PRNewswire/ — Telik, Inc. (Nasdaq: TELK – News) currently voiced that a Phase 2 investigator-led Telcyta hearing in hematologic malignancies has been stretched to an one more investigational site, Memorial Sloan-Kettering Cancer Center (MSKCC). Based upon a formula celebrated in Stage 1 of a trial, that is being conducted during a Robert Wood Johnson University Hospital underneath a citation of Joseph R. Bertino, MD of The Cancer Institute of New Jersey, an one more 10 patients with chemotherapy resistant mixed myeloma might be enrolled. Additional hearing investigators during MSKCC have been Sergio A. Giralt, MD as well as Nikoletta Lendvai, MD, PhD.
Telik, Inc. of Palo Alto, CA, is a clinical theatre drug growth association focused upon finding as well as building tiny proton drug to provide cancer. The company’s many modernized drug claimant is Telintra®, a mutated glutathione analog dictated for a diagnosis of hematologic malignancies together with myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for a diagnosis of a accumulation of cancers. Telik’s product possibilities were detected regulating a exclusive drug find technology, TRAP®, that enables a fast as well as fit find of tiny proton drug candidates.
Telik, a Telik logo, TELINTRA, TELCYTA as well as TRAP have been trademarks or purebred trademarks of Telik, Inc.
glutathione – Bing News